Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 plus BCG in Non-Muscle Invasive Bladder Cancer
NCT02138734Phase 2Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2014
- Primary completion
- Sep 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of nogapendekin alfa inbakicept in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by ImmunityBio, Inc. Primary endpoints: Complete Response Rate at 6 Months and Disease Free Survival. Started Jul 2014; status: active, not recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02138734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138734.